Breaking News, Collaborations & Alliances

Hoth Therapeutics Selects Nuvisan to Manufacture Clinical Batches of HT-001

Will use the topical drug product for its upcoming CLEER-001 clinical trial for cancer patients.

Author Image

By: Charlie Sternberg

Associate Editor

Hoth Therapeutics Inc., a patient-focused biopharmaceutical company, has signed an agreement with Nuvisan, a European CRO/CDMO with topical manufacturing capabilities in Sophia-Antipolis, France, to manufacture clinical batches of HT-001 topical drug product for its upcoming CLEER-001 clinical trial for cancer patients.   HT-001 is a novel topical therapy in development for treatment of cutaneous toxicities associated with Epidermal Growth Factor Receptor (EGFR) inhibitor cancer therapy.   N...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters